{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:58:02Z","timestamp":1790506682080,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T00:00:00Z","timestamp":1595116800000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.revmed.2019.04.007","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:55:06Z","timestamp":1558540506000},"page":"508-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Actualit\u00e9s physiopathologiques et th\u00e9rapeutiques dans l\u2019asthme s\u00e9v\u00e8re"],"prefix":"10.1016","volume":"40","author":[{"given":"D.","family":"Hassoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.X.","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Magnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2019.04.007_bib0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40248-016-0073-0","article-title":"Asthma-related deaths","volume":"11","author":"D\u2019Amato","year":"2016","journal-title":"Multidiscip Respir Med"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0325","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.rmr.2009.09.001","article-title":"Asthma in France: a review of descriptive epidemiological data","volume":"27","author":"Delmas","year":"2009","journal-title":"Rev Mal Respir"},{"issue":"3","key":"10.1016\/j.revmed.2019.04.007_bib0330","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A summary of the new GINA strategy: a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0335","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0340","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart Lung, and Blood Institute's Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.revmed.2019.04.007_bib0345","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.rmed.2005.06.012","article-title":"An international observational prospective study to determine the cost of asthma exacerbations (COAX)","volume":"100","author":"Lane","year":"2006","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.revmed.2019.04.007_bib0350","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0355","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.revmed.2019.04.007_bib0360","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0365","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaci.2014.04.038","article-title":"Prognostic value of cluster analysis of severe asthma phenotypes","volume":"134","author":"Bourdin","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2019.04.007_bib0370","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10118","key":"10.1016\/j.revmed.2019.04.007_bib0375","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"Pavord","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0380","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1172\/JCI8107","article-title":"Myeloid dendritic cells induce Th2\u00a0responses to inhaled antigen, leading to eosinophilic airway inflammation","volume":"106","author":"Lambrecht","year":"2000","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0385","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.4049\/jimmunol.164.4.2142","article-title":"The effect of IL-5\u00a0and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity","volume":"164","author":"Mould","year":"2000","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.revmed.2019.04.007_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0395","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaci.2005.08.035","article-title":"Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma","volume":"116","author":"Mascia","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2019.04.007_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2\u00a0innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0405","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0410","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.revmed.2019.04.007_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.10.011","article-title":"Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis","volume":"133","author":"Moore","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.revmed.2019.04.007_bib0420","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.revmed.2019.04.007_bib0425","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1164\/rccm.201405-0859PP","article-title":"IL-17\u00a0in severe asthma. Where do we stand?","volume":"190","author":"Chesne","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0430","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1183\/09031936.00019810","article-title":"Pathophysiology of bronchial smooth muscle remodelling in asthma","volume":"36","author":"Bara","year":"2010","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.revmed.2019.04.007_bib0435","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.201402-0314OC","article-title":"Impaired nuclear translocation of the glucocorticoid receptor in corticosteroid-insensitive airway smooth muscle in severe asthma","volume":"191","author":"Chang","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0440","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.201512-2452OC","article-title":"A Transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED","volume":"195","author":"Kuo","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.revmed.2019.04.007_bib0445","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","article-title":"U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics","volume":"139","author":"Lefaudeux","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0450","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2\u00a0molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0455","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1183\/13993003.01129-2016","article-title":"Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study","volume":"48","author":"Wilson","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0460","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cea.13085","article-title":"IL-6\u00a0pathway upregulation in subgroup of severe asthma is associated with neutrophilia and poor lung function","volume":"48","author":"Turan","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0465","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2017.02.045","article-title":"Sputum transcriptomics reveal upregulation of IL-1\u00a0receptor family members in patients with severe asthma","volume":"141","author":"Rossios","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0470","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.revmed.2019.04.007_bib0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203874","article-title":"Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort","volume":"13","author":"Emma","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0480","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02173-2017","article-title":"Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis","volume":"51","author":"Takahashi","year":"2018","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.revmed.2019.04.007_bib0485","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.revmed.2019.04.007_bib0490","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.rmed.2010.06.001","article-title":"Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data","volume":"104","author":"Molimard","year":"2010","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0495","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"issue":"13","key":"10.1016\/j.revmed.2019.04.007_bib0500","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.revmed.2019.04.007_bib0505","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.revmed.2019.04.007_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.revmed.2019.04.007_bib0515","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.revmed.2019.04.007_bib0520","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.revmed.2019.04.007_bib0525","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3\u00a0trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0530","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3\u00a0study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.revmed.2019.04.007_bib0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10056","key":"10.1016\/j.revmed.2019.04.007_bib0540","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3\u00a0trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.revmed.2019.04.007_bib0545","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5\u00a0receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.revmed.2019.04.007_bib0550","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2019.04.007_bib0555","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cea.12853","article-title":"Comparison of anti-interleukin-5\u00a0therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials","volume":"47","author":"Cabon","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"10039","key":"10.1016\/j.revmed.2019.04.007_bib0560","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2\u00a0agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.revmed.2019.04.007_bib0565","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.revmed.2019.04.007_bib0570","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.revmed.2019.04.007_bib0575","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1\u00a0and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3\u00a0clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.revmed.2019.04.007_bib0580","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0585","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00948-2018","article-title":"Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma","volume":"53","author":"Busse","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.revmed.2019.04.007_bib0590","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(16)30179-5","article-title":"Fevipiprant, a prostaglandin D2\u00a0receptor 2\u00a0antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial","volume":"4","author":"Gonem","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.revmed.2019.04.007_bib0595","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0600","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/rccm.200707-1134OC","article-title":"Clarithromycin targets neutrophilic airway inflammation in refractory asthma","volume":"177","author":"Simpson","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0605","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.revmed.2019.04.007_bib0610","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.200903-0354OC","article-title":"Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial","volume":"181","author":"Castro","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.revmed.2019.04.007_bib0615","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2013.08.009","article-title":"Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma","volume":"132","author":"Wechsler","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.revmed.2019.04.007_bib0620","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2466-11-8","article-title":"Long-term (5\u00a0year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial","volume":"11","author":"Thomson","year":"2011","journal-title":"BMC Pulm Med"},{"issue":"4","key":"10.1016\/j.revmed.2019.04.007_bib0625","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaci.2016.08.009","article-title":"Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations","volume":"139","author":"Pretolani","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.revmed.2019.04.007_bib0315","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1164\/rccm.201407-1374LE","article-title":"Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma","volume":"190","author":"Pretolani","year":"2014","journal-title":"Am J Respir Crit Care Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319304412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866319304412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:17Z","timestamp":1759336877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866319304412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0248866319304412"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2019.04.007","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s physiopathologiques et th\u00e9rapeutiques dans l\u2019asthme s\u00e9v\u00e8re","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2019.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}